THE EFFECT OF INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF COATS DISEASE IN CHILDREN

Abstract

Intravitreal bevacizumab appears to be a well-tolerated treatment for children with Coats disease. A favorable response is observed when compared with other treatment modalities. It has the potential as an adjuvant therapy of vascular ablative procedures to improve final vision and facilitate ongoing treatment.